ProShares UltraShort NASDAQ Biotechnology
7 hedge funds and large institutions have $2.94M invested in ProShares UltraShort NASDAQ Biotechnology in 2022 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 1 closing their positions.
23% more capital invested
Capital invested by funds: $2.39M → $2.94M (+$546K)
5.52% more ownership
Funds ownership: 11.1% → 16.62% (+5.5%)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
13% less funds holding
Funds holding: 8 → 7 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.2M |
| 2 |
IMC Chicago
Chicago,
Illinois
|
+$55.2K |
| 3 |
Morgan Stanley
New York
|
+$758 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OMC
Old Mission Capital
Chicago,
Illinois
|
-$413K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$217K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$19.5K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$9.47K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $1.49M | +$1.2M | +25,432 | +636% |
|
|
2
Citadel Advisors
Miami,
Florida
| $652K | -$217K | -4,583 | -26% |
|
|
3
IMC Chicago
Chicago,
Illinois
| $590K | +$55.2K | +1,166 | +11% |
|
|
TRCT
4
Tower Research Capital (TRC)
New York
| $205K | -$19.5K | -411 | -9% |
|
|
5
Morgan Stanley
New York
| $3K | +$758 | +16 | +42% |
|
6
Citigroup
New York
| $2K | – | – | – |
|
|
OMC
7
Old Mission Capital
Chicago,
Illinois
| – | -$413K | -7,656 | Closed |
|
|
8
UBS Group
Zurich,
Switzerland
| – | -$9.47K | -200 | -100% |
|
BIS Hedge Fund Activity: Q3 2022 in Review
7 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraShort NASDAQ Biotechnology (BIS) for Q3 2022, worth a combined $2.94M — up 23% from $2.39M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of BIS and 0 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 3 added.
The largest buyer was Susquehanna International Group, adding an estimated $1.2M. The largest seller was Old Mission Capital, exiting entirely with an estimated $413K sold.
- 7 institutional investors held ProShares UltraShort NASDAQ Biotechnology (BIS) as of Q3 2022, down from 8 in Q2 2022.
- Funds reported $2.94M of ProShares UltraShort NASDAQ Biotechnology stock for Q3 2022, up 23% quarter-over-quarter.
- 0 funds opened new ProShares UltraShort NASDAQ Biotechnology positions in Q3 2022 and 1 closed out, a net change of -1 holder.
- The largest ProShares UltraShort NASDAQ Biotechnology buyer in Q3 2022 was Susquehanna International Group, an estimated $1.2M added.
- The largest ProShares UltraShort NASDAQ Biotechnology seller in Q3 2022 was Old Mission Capital, an estimated $413K sold.
Based on aggregated 13F filings for Q3 2022.